Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX + Adebrelimab + PULSAR in Advanced PDAC
NCT07595172Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, NALIRIFOX in pancreatic ductal adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Started Apr 2026; status: recruiting.
02
Drugs
adebrelimabNALIRIFOX
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07595172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595172.